Irisin protected hemopoietic stem cells and improved outcome of severe bone marrow failure
Hui Li,Dexiao Kong,Yi Zhao,Xia Liu,Fang Xiao,Xiaoyan Li,Jianting Hu,Yingjie Chen,Shengli Li,Baozhu Wang,Yuan Chen,Yang Jiang,Xiaoli Liu,Xiumei Feng,Yanan Guo,Xiaoli Feng,Jing Ren,Fang Wang,Ying Han,William Donelan,Lijun Yang,Dawei Xu,Dongqi Tang,Chengyun Zheng
DOI: https://doi.org/10.1016/j.biopha.2023.115863
IF: 7.419
2023-12-01
Biomedicine & Pharmacotherapy
Abstract:Acquired aplastic anemia (AA) is a bone marrow failure (BMF) disease, characterized by fatty bone marrow (BM) and BM hypocellularity resulted from auto-immune dysregulated T cells-mediated destruction of BM haemopoietic stem cells (HPSC). The objective of this study was to investigate potential therapeutic effect of irisin, a molecule involved in adipose tissue transition, on AA mouse model. Our results showed that the concentration of irisin in serum was lower in AA patients than in healthy controls, suggesting a role of irisin in the pathogenesis of AA. In the AA mice, irisin administration prolonged the survival rate, prevented or attenuated peripheral pancytopenia, and preserved HPSC in the BM. Moreover, irisin also markedly reduced BM adipogenesis. In vitro results showed that irisin increased both cell proliferation and colony numbers of HPSC. Furthermore, our results demonstrated that irisin upregulated the expression of mitochondrial ATPase Inhibitory Factor 1 (IF1) in HPSC, inhibited the activation of mitochondrial fission protein (DRP1) and enhanced aerobic glycolysis. Taken together, our findings indicate novel roles of irisin in the pathogenesis of AA, and in the protection of HPSC through stimulation of proliferation and regulation of mitochondria function, which provides a proof-of-concept for the application of irisin in AA therapy.
pharmacology & pharmacy,medicine, research & experimental